Skip to content

Author

Yi Zhan

We have 2 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.

It is demonstrated that compensatory AKT activation limits the efficacy of cabozantinib in ALL and the combination of cabozantinib and capivasertib as a promising therapeutic strategy for refractory ALL is established.

Hai-Hong Gao, Yi Zhan, Miao-Ying Bao et al. · 0 citations
Open access Aug 2026

Untargeted metabolomics reveals differential metabolic pathways and biomarkers in the acute phase of Kawasaki disease

Untargeted metabolomics enables identification of metabolically perturbed pathways during the acute phase of KD, and L-tyrosine, L-tryptophan, glutamine, histidine, histamine, and taurocholic acid may serve as candidate biomarkers for acute phase of KD.

Han-Qi Dai, Qian-Wen Wang, Yi Zhan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.